Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
Workday
WDAY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash cash equivalents and federal funds sold | -23.23%169.14M | -23.23%169.14M | -62.15%138.67M | -42.38%171.62M | -21.84%190.85M | 173.27%220.33M | 173.27%220.33M | 134.98%366.37M | 92.41%297.86M | 13.01%244.18M |
-Cash and cash equivalents | -23.23%169.14M | -23.23%169.14M | -62.15%138.67M | -42.38%171.62M | -21.84%190.85M | 173.27%220.33M | 173.27%220.33M | 134.98%366.37M | 92.41%297.86M | 13.01%244.18M |
Receivables | -13.04%5.3M | -13.04%5.3M | -6.05%5.25M | 27.74%6.4M | 1.46%5.92M | -7.69%6.09M | -7.69%6.09M | -6.50%5.59M | -13.15%5.01M | -8.81%5.84M |
-Accounts receivable | -13.04%5.3M | -13.04%5.3M | -6.05%5.25M | 27.74%6.4M | 1.46%5.92M | -7.69%6.09M | -7.69%6.09M | -6.50%5.59M | -13.15%5.01M | -8.81%5.84M |
Net loan | -1.18%1.31B | -1.18%1.31B | 5.56%1.39B | 1.18%1.35B | 1.30%1.34B | -6.70%1.32B | -6.70%1.32B | -11.15%1.31B | -11.93%1.33B | -9.29%1.32B |
-Gross loan | -1.20%1.33B | -1.20%1.33B | 5.30%1.41B | 0.90%1.37B | 0.62%1.36B | -7.02%1.34B | -7.02%1.34B | -11.51%1.34B | -11.64%1.36B | -8.97%1.35B |
-Allowance for loans and lease losses | -2.24%21.09M | -2.24%21.09M | -8.74%21.92M | -15.18%20.34M | -35.49%16.01M | -23.15%21.57M | -23.15%21.57M | -17.29%24.02M | 26.40%23.98M | 28.59%24.81M |
Securities and investments | -10.07%25.69M | -10.07%25.69M | 4.76%27.43M | -1.19%27.33M | -2.89%27.91M | -0.10%28.57M | -0.10%28.57M | -10.25%26.18M | -11.27%27.66M | -14.81%28.74M |
-Short term investments | -10.07%25.69M | -10.07%25.69M | 4.76%27.43M | -1.19%27.33M | -2.89%27.91M | -0.10%28.57M | -0.10%28.57M | -10.25%26.18M | -11.27%27.66M | -14.81%28.74M |
Federal home loan bank stock | -33.51%2.7M | -33.51%2.7M | 0.33%3.62M | 54.76%5.12M | 16.48%3.61M | -4.92%4.06M | -4.92%4.06M | 5.68%3.61M | -11.59%3.31M | 294.27%3.1M |
Bank owned life insurance | 2.87%46.02M | 2.87%46.02M | 2.80%45.68M | 2.73%45.36M | 2.63%45.04M | 2.57%44.74M | 2.57%44.74M | 2.51%44.44M | 2.48%44.15M | 2.47%43.88M |
Net PPE | -18.78%13.62M | -18.78%13.62M | -18.80%13.81M | -4.89%16.42M | -4.42%16.57M | -4.31%16.77M | -4.31%16.77M | -4.17%17.01M | -3.63%17.26M | -4.32%17.34M |
-Gross PPE | -53.30%13.62M | -53.30%13.62M | -18.80%13.81M | -4.89%16.42M | -4.42%16.57M | 0.61%29.16M | 0.61%29.16M | -4.17%17.01M | -3.63%17.26M | -4.32%17.34M |
-Accumulated depreciation | ---- | ---- | ---- | ---- | ---- | -8.13%-12.39M | -8.13%-12.39M | ---- | ---- | ---- |
Foreclosed assets | ---- | ---- | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 |
Other assets | -19.43%11.39M | -19.43%11.39M | -23.20%12.28M | -36.98%10.75M | -23.80%15.24M | -13.04%14.14M | -13.04%14.14M | -45.28%15.99M | -1.43%17.06M | 32.22%20M |
Total assets | -4.62%1.59B | -4.62%1.59B | -8.86%1.65B | -6.52%1.65B | -2.55%1.66B | 2.07%1.67B | 2.07%1.67B | 1.96%1.81B | -1.48%1.76B | -5.01%1.7B |
Liabilities | ||||||||||
Total deposits | -1.67%1.31B | -1.67%1.31B | -13.51%1.29B | -12.67%1.26B | -5.12%1.33B | 4.04%1.33B | 4.04%1.33B | 1.24%1.49B | 0.57%1.45B | -7.77%1.4B |
Current debt and capital lease obligation | -63.16%35M | -63.16%35M | 43.75%115M | 97.14%138M | 60.00%80M | -12.44%95M | -12.44%95M | --80M | -10.26%70M | --50M |
-Current debt | -63.16%35M | -63.16%35M | 43.75%115M | 97.14%138M | 60.00%80M | -12.44%95M | -12.44%95M | --80M | -10.26%70M | --50M |
Long term debt and capital lease obligation | -3.19%13.43M | -3.19%13.43M | -3.17%13.49M | -1.73%13.75M | -38.78%13.81M | -38.67%13.87M | -38.67%13.87M | -83.58%13.93M | -21.56%13.99M | 26.26%22.55M |
-Long term debt | -1.38%9.56M | -1.38%9.56M | -1.37%9.6M | -1.36%9.63M | -47.19%9.66M | -47.09%9.7M | -47.09%9.7M | -87.91%9.73M | -27.68%9.76M | 35.53%18.3M |
-Long term capital lease obligation | -7.41%3.86M | -7.41%3.86M | -7.34%3.89M | -2.58%4.12M | -2.66%4.14M | -2.59%4.17M | -2.59%4.17M | -2.53%4.2M | -2.49%4.23M | -2.43%4.26M |
Other liabilities | -43.51%4.7M | -43.51%4.7M | -29.74%5.06M | -58.00%6.06M | -60.42%5.63M | -54.17%8.32M | -54.17%8.32M | -46.18%7.21M | 16.36%14.44M | -7.21%14.23M |
Total liabilities | -5.96%1.36B | -5.96%1.36B | -10.61%1.42B | -8.02%1.42B | -3.97%1.43B | 1.37%1.45B | 1.37%1.45B | 1.35%1.59B | -0.10%1.55B | -4.16%1.49B |
Shareholders'equity | ||||||||||
Share capital | 0.56%178K | 0.56%178K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | -0.56%177K |
-common stock | 0.56%178K | 0.56%178K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | 0.00%177K | -0.56%177K |
-Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Paid-in capital | 1.06%125.45M | 1.06%125.45M | 1.01%125.06M | 0.99%124.67M | 1.03%124.42M | 1.04%124.13M | 1.04%124.13M | 1.14%123.81M | 1.37%123.44M | 0.52%123.14M |
Retained earnings | 6.85%113.56M | 6.85%113.56M | 5.15%108.68M | 7.01%107.96M | 14.20%111.27M | 12.32%106.29M | 12.32%106.29M | 12.45%103.36M | -21.11%100.89M | -20.75%97.43M |
Gains losses not affecting retained earnings | -8.62%-1.63M | -8.62%-1.63M | 53.99%-1.1M | 13.43%-1.64M | -2.10%-1.6M | 32.00%-1.5M | 32.00%-1.5M | 1.68%-2.39M | -14.19%-1.89M | -151.04%-1.57M |
Other equity interest | 10.01%-6.47M | 10.01%-6.47M | 9.77%-6.65M | 9.52%-6.83M | 9.30%-7.01M | 9.09%-7.19M | 9.09%-7.19M | 8.89%-7.37M | 8.70%-7.55M | 8.51%-7.73M |
Total stockholders'equity | 4.14%231.09M | 4.14%231.09M | 3.94%226.16M | 4.31%224.34M | 7.47%227.24M | 6.92%221.9M | 6.92%221.9M | 6.67%217.58M | -10.35%215.07M | -10.61%211.45M |
Total equity | 4.14%231.09M | 4.14%231.09M | 3.94%226.16M | 4.31%224.34M | 7.47%227.24M | 6.92%221.9M | 6.92%221.9M | 6.67%217.58M | -10.35%215.07M | -10.61%211.45M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |